TFDP2 Antibody

What is TFDP2 and why is it important to study?

TFDP2 (Transcription Factor Dp-2) is a critical cofactor that forms heterodimers with E2F transcription factors, resulting in transcriptional activation of cell cycle-regulated genes. This protein plays an essential role in controlling cell-cycle progression from G1 to S phase .

The significance of studying TFDP2 stems from its involvement in:

• Cell cycle regulation and proliferation control

• Transcriptional activation of multiple target genes

• Association with diseases including Retinoblastoma and Alstrom Syndrome

• Critical role in erythropoiesis and hematopoietic differentiation

TFDP2 binds DNA cooperatively with E2F family members through the E2 recognition site (5'-TTTC[CG]CGC-3') found in promoter regions of genes involved in cell cycle regulation or DNA replication .

What types of TFDP2 antibodies are available for research?

Several types of TFDP2 antibodies are available for research applications, including:

When selecting an antibody, consider the specific application, experimental model species, and whether conjugation to reporter molecules is needed for your particular experimental design .

What are the validated applications for TFDP2 antibodies?

TFDP2 antibodies have been validated for various experimental applications:

It is recommended to titrate antibodies in each testing system to obtain optimal results, as performance can be sample-dependent .

How should TFDP2 antibodies be stored and handled?

Proper storage and handling of TFDP2 antibodies are crucial for maintaining their functionality:

• Standard storage temperature: -20°C for most antibodies; some recombinant formats require -80°C storage

• Buffer conditions:

  • PBS with 0.02% sodium azide and 50% glycerol pH 7.3 for standard antibodies

  • PBS only (BSA and azide free) for conjugation-ready formats

• Stability: Typically stable for one year after shipment when stored properly

• Aliquoting: For standard antibodies stored at -20°C, aliquoting is generally unnecessary

• Working concentration: Typically 1 mg/mL for recombinant antibodies ready for conjugation

For optimal performance, avoid repeated freeze-thaw cycles and follow manufacturer-specific guidelines for each antibody format.

How can I optimize TFDP2 knockdown experiments to study its function?

When designing TFDP2 knockdown experiments, consider these methodological approaches based on published research:

Effective knockdown methods:

• shRNA-mediated knockdown has been validated for TFDP2 using retroviral expression systems

• siRNA approach has been successful with at least two targeting sequences to confirm specificity

Experimental design considerations:

• Validation of knockdown efficiency:

  • Quantify knockdown at both mRNA level by RT-qPCR and protein level by Western blot

  • Expect >70% reduction in expression for functional impact assessment

• Functional readouts:

  • Cell proliferation: Count cells using a hematocytometer at 24 and 48 hours post-knockdown

  • Cell cycle analysis: Flow cytometry to detect accumulation in S phase

  • Gene expression changes: RT-qPCR for downstream targets (e.g., hemoglobin chains, GATA1, cell cycle genes)

• Controls:

  • Use non-targeting shRNA/siRNA (e.g., Luciferase control shRNA)

  • Monitor GFP+ percentages for infection efficiency in viral systems

  • Include rescue experiments with TFDP2 overexpression to confirm specificity

In erythroid cell models, TFDP2 knockdown resulted in significantly reduced rates of proliferation and impaired induction of erythroid-important genes, with cells accumulating in S phase .

What methodologies are effective for studying TFDP2-E2F interactions?

Investigating TFDP2-E2F interactions requires multiple complementary approaches:

Biochemical interaction studies:

• Co-immunoprecipitation:

  • Use TFDP2 antibodies for IP followed by E2F detection or vice versa

  • IP conditions: 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

  • Controls should include IgG and reverse IP validation

• Chromatin Immunoprecipitation (ChIP):

  • Target the E2 recognition site (5'-TTTC[CG]CGC-3') in promoter regions

  • Analyze co-occupancy of TFDP2 and E2F factors at target promoters

  • Consider sequential ChIP to identify simultaneous binding

Functional interaction studies:

• Luciferase reporter assays:

  • Design reporters containing E2F-binding elements

  • Compare activity with TFDP2 alone, E2F alone, and TFDP2+E2F combination

  • Similar approaches have been used to study TFDP2 promoter regulation

• Protein domain mapping:

  • Use deletion mutants to identify specific regions required for interaction

  • Focus on conserved domains between TFDP family members

TFDP2-E2F2 constitutes a particularly important pair in erythroid differentiation, with both factors being highly induced during terminal erythropoiesis .

How does TFDP2 expression and function differ across cell types and tissues?

TFDP2 shows differential expression and function across various cell types and tissues:

Expression patterns:

• Erythroid cells: TFDP2 is highly upregulated during terminal erythropoiesis, with greatest induction at the R2 to R3 transition, while TFDP1 is downregulated

• Brain tissue: Detectable expression with validated antibody reactivity

• Heart tissue: Validated expression in mouse models

• Other tissues: Detected in kidney, blood, embryonic tissue, thyroid, liver, uterus, placenta, prostate

Functional differences:

• Erythroid cells: Partners with E2F2; critical for:

  • Cell cycle control during terminal differentiation

  • Regulation of erythroid-important genes including hemoglobin chains

  • Proper enucleation processes

• Viral-infected cells:

  • Upregulated in PRRSV-infected cells

  • Positively regulates cyclin A expression

  • Contributes to viral proliferation

• Adipocytes:

  • Blocks adipocyte differentiation by repressing CEBPA binding to target gene promoters

These tissue-specific functions highlight the importance of selecting appropriate experimental models when studying TFDP2 function in specific biological contexts.

What are the best approaches for analyzing TFDP2 promoter regulation and transcriptional control?

For studying TFDP2 promoter regulation, consider these methodological approaches:

Promoter analysis techniques:

• Luciferase reporter assays:

  • Create promoter-reporter constructs with different regions of the TFDP2 promoter

  • Design truncated mutants to identify key regulatory elements

  • Example: The −17/400-Luc construct of TFDP2 promoter showed 1.6-fold upregulation upon PRRSV infection

  • Mutate specific transcription factor binding sites to confirm functional relevance

• Site-directed mutagenesis of regulatory elements:

  • Key binding sites identified include C/EBPβ (-11 to -4), ATF-1 (+30 to +40), AP-1 (+37 to +43), and SP1 (+79 to +87)

  • Mutation of C/EBPβ binding site specifically impaired PRRSV-induced activation

• ChIP analysis:

  • GATA1 and TAL1 bind to regulatory regions of TFDP2 in erythroid cells

  • Two regions of co-occupancy: promoter region 5′ of transcriptional start site (H3K4me3-positive, H3K4me1-negative) and an intronic enhancer element

• Dose-dependency experiments:

  • Test transcription factor dose-response relationships with the TFDP2 promoter

  • Example: N protein induced TFDP2 promoter activity in a dose-dependent manner

Model data from published research:
TFDP2 promoter luciferase assay in PRRSV context showed that regulatory elements exist in the -17 to +400 bp region, with the C/EBPβ binding site being the primary responsive element .

What considerations are important when using TFDP2 antibodies for detecting post-translational modifications?

When investigating post-translational modifications (PTMs) of TFDP2, consider these methodological approaches:

Technical considerations:

• Antibody selection:

  • Standard TFDP2 antibodies detect total protein regardless of modification state

  • For PTM-specific detection, specialized antibodies targeting specific modifications would be needed

  • Consider phospho-specific antibodies if studying TFDP2 phosphorylation

• Sample preparation:

  • Include phosphatase inhibitors when studying phosphorylation

  • Add proteasome inhibitors if studying ubiquitination

  • Consider nuclear extraction protocols as TFDP2 functions primarily in the nucleus

• Specialized techniques:

  • Phos-tag SDS-PAGE for detecting multiple phosphorylated species

  • Immunoprecipitation with TFDP2 antibodies followed by Western blotting with PTM-specific antibodies

  • Mass spectrometry for comprehensive PTM mapping

Functional relevance:

• Phosphorylation may regulate TFDP2's interaction with E2F factors

• PTMs could affect DNA binding capacity or subcellular localization

• Modifications may be cell cycle-dependent or tissue-specific

While the search results don't specifically address TFDP2 post-translational modifications, the regulation of cell cycle factors commonly involves phosphorylation events, suggesting this as a productive area for future research.

How can I optimize Western blot protocols for detecting TFDP2 protein?

For optimal Western blot detection of TFDP2, follow these methodological recommendations:

Protocol optimization:

• Sample preparation:

  • Validated samples include human brain tissue and mouse heart tissue

  • Use appropriate lysis buffers containing protease inhibitors

  • For cellular fractionation, focus on nuclear extracts where TFDP2 primarily localizes

• Electrophoresis conditions:

  • Use 12% SDS-PAGE for optimal separation

  • Expected molecular weight: 49 kDa

• Transfer settings:

  • Transfer to PVDF membranes (validated in published protocols)

  • Use wet transfer for optimal results with transcription factors

• Antibody conditions:

  • Primary antibody dilution: 1:500-1:1000

  • Incubation: Overnight at 4°C

  • Secondary antibody: HRP-conjugated, 1:5000 dilution

  • Visualization: ECL substrate systems have been validated

• Controls:

  • Positive controls: Human brain tissue, mouse heart tissue

  • Loading control: β-actin antibody (1:5000)

  • For overexpression studies: FLAG-tagged constructs can be detected with anti-FLAG (1:5000)

Troubleshooting tips:

• If background is high, increase blocking time or BSA concentration

• For weak signals, extend exposure time or increase antibody concentration

• To confirm specificity, use lysates from TFDP2 knockdown experiments as negative controls

What approaches should be used to investigate TFDP2's role in cell cycle regulation?

To investigate TFDP2's role in cell cycle regulation, implement these methodological approaches:

Experimental designs:

• Cell cycle analysis by flow cytometry:

  • Measure DNA content using propidium iodide staining

  • Quantify cell distribution across G0/G1, S, and G2/M phases

  • Compare TFDP2 knockdown or overexpression to controls

  • Expected phenotype: TFDP2 loss causes accumulation in S phase

• BrdU incorporation assays:

  • Pulse cells with BrdU to label actively replicating DNA

  • Analyze by flow cytometry or immunofluorescence

  • Quantify differences in S-phase entry/progression

• Time-lapse microscopy:

  • Track individual cells through division cycles

  • Measure timing of cell cycle progression

  • Identify specific cell cycle phase affected by TFDP2 manipulation

• Cell proliferation assays:

  • Count cells at 24 and 48 hours post-manipulation

  • Use hematocytometer or automated cell counters

  • TFDP2 knockdown results in significantly reduced proliferation rates

Molecular mechanisms:

• Target gene expression analysis:

  • Examine known E2F target genes involved in cell cycle

  • Knockdown of TFDP2 inhibits normal downregulation of many E2F2 target genes

  • Focus on genes regulating G1/S transition

• Cyclin expression analysis:

  • TFDP2 positively regulates cyclin A expression

  • Monitor cyclins D, E, A, and B by Western blot or qPCR

• Cell size measurements:

  • Loss of TFDP2 results in increased cell size

  • Use flow cytometry forward scatter or cell analyzers for quantification

How can I effectively design experiments to study TFDP2 in disease models?

When investigating TFDP2 in disease contexts, consider these experimental approaches:

Disease-specific models:

• Cancer models:

  • TFDP2 is associated with retinoblastoma

  • Also implicated in head and neck neoplasms, female urogenital diseases, and thyroid diseases

  • Compare TFDP2 expression between tumor and normal tissues

  • Correlate TFDP2 expression with clinical outcomes

• Viral infection models:

  • PRRSV infection upregulates TFDP2 expression

  • Examine cellular response to viral challenge with and without TFDP2 modulation

  • Measure viral replication/proliferation as a readout

• Developmental disorders:

  • TFDP2 is associated with Alstrom Syndrome

  • Study in embryonic tissues where TFDP2 expression has been documented

Experimental approaches:

• Expression analysis in patient samples:

  • Immunohistochemistry on tissue microarrays

  • qPCR from patient biopsies

  • Western blot from patient-derived samples

• Functional studies in disease-relevant cell lines:

  • TFDP2 knockdown or overexpression

  • Rescue experiments to validate causality

  • Drug sensitivity studies to assess therapeutic implications

• Pathway analysis:

  • Focus on relevant pathways:

    • E2F Transcription Factor Network

    • Cell Cycle Pathway

    • G1 to S Cell Cycle Control

    • TGF-beta Receptor Signaling

• Animal models:

  • Generate conditional knockout models in tissues of interest

  • Analyze phenotypic consequences in disease-relevant systems

  • Expected phenotypes might include proliferation defects, differentiation abnormalities, or cell cycle dysregulation

What are the advantages and limitations of different antibody formats for TFDP2 detection?

Different TFDP2 antibody formats offer distinct advantages and limitations:

Method selection guidance:

• For exploratory research in novel systems, begin with polyclonal antibodies

• For quantitative, reproducible assays, use recombinant monoclonals

• For multiplex systems or when multiple antibodies are needed, recombinant formats offer conjugation flexibility

• Consider species reactivity based on your experimental model

How do different cell cycle analysis methods compare when studying TFDP2 function?

When investigating TFDP2's cell cycle functions, several analytical methods offer complementary insights:

Integrated approach recommendation:
For comprehensive analysis of TFDP2's cell cycle function, combine:

• Flow cytometry for cell cycle distribution

• Gene expression analysis of E2F targets and cyclins

• BrdU incorporation for S-phase dynamics

• Cell proliferation counts for functional outcomes

This multi-method approach provides both quantitative measurements and mechanistic insights into TFDP2's role in cell cycle regulation.

How can ChIP-seq be optimized to study TFDP2 genomic binding sites?

Optimizing ChIP-seq for TFDP2 binding site analysis requires careful experimental design:

Protocol optimization:

• Antibody selection:

  • Use antibodies validated for immunoprecipitation (e.g., 11500-1-AP)

  • Test antibody efficiency with pilot ChIP-qPCR at known targets

  • Consider multiple antibodies targeting different epitopes

• Crosslinking conditions:

  • Standard: 1% formaldehyde for 10 minutes at room temperature

  • For indirect binding through protein complexes (like with E2F factors), consider dual crosslinking with DSG followed by formaldehyde

• Sonication parameters:

  • Optimize to achieve fragments of 200-500 bp

  • Verify fragmentation by gel electrophoresis

  • Cell-type specific optimization may be required

• IP conditions:

  • Use 5-10 μg antibody per ChIP reaction

  • Include IgG and input controls

  • For low abundance factors, increase cell numbers

Data analysis considerations:

• Peak calling:

  • Look for the E2 recognition site (5'-TTTC[CG]CGC-3') in enriched regions

  • Compare with known E2F binding sites

  • Use appropriate peak calling algorithms (MACS2, HOMER)

• Integrative analysis:

  • Compare TFDP2 binding with E2F family member binding patterns

  • Correlate with gene expression data

  • Examine histone modifications at binding sites (H3K4me3 for promoters, H3K4me1 for enhancers)

• Motif analysis:

  • De novo motif discovery to identify TFDP2-associated sequences

  • Comparison with known E2F motifs

  • Search for co-occurring transcription factor motifs

Example from literature:
In erythroid cells, TFDP2 regulation involves GATA1 and TAL1 binding to its regulatory regions, with one peak in the promoter region and a second peak in the first intron representing a potential enhancer element .

What are the best practices for studying TFDP2 in differentiation models?

When investigating TFDP2's role in cellular differentiation, consider these methodological approaches:

Model systems:

• Erythroid differentiation:

  • Primary mouse fetal liver erythroid progenitor cultures

  • Erythroleukemia cell lines (MEL, K562)

  • Monitor stages R1-R4 of erythroid maturation

• Adipocyte differentiation:

  • 3T3-L1 preadipocyte model

  • Primary preadipocytes

  • Relevance: TFDP2 blocks adipocyte differentiation by repressing CEBPA binding

• Other differentiation systems:

  • Neural differentiation models

  • Myogenic differentiation

  • Embryonic development contexts

Experimental approaches:

• Expression profiling during differentiation:

  • Track TFDP2 expression across differentiation stages

  • In erythropoiesis, TFDP2 is upregulated while TFDP1 is downregulated

  • Use RT-qPCR for specific time points

  • RNA-seq for global expression patterns

• Loss and gain of function:

  • shRNA or siRNA knockdown at specific differentiation stages

  • Inducible expression systems

  • CRISPR/Cas9 genome editing for complete knockout

  • Expected phenotypes in erythroid models: reduced proliferation, impaired induction of lineage-specific genes

• Lineage marker analysis:

  • Track differentiation-specific markers

  • In erythroid cells: hemoglobin chains (Hbb-b1, Hba-a1), GATA1, Epb4.1

  • Cell morphology and maturation assessment

• Cell cycle coordination:

  • TFDP2 couples cell cycle with differentiation

  • Analyze cell cycle distribution during differentiation stages

  • Study relationship between proliferation arrest and maturation

Protocol example from erythroid studies:

• Infect lineage-negative mouse fetal erythroid progenitor cells with TFDP2 shRNA

• Monitor GFP+ percentages by flow cytometry for infection efficiency

• Count cells at 24 and 48 hours to measure proliferation effects

• Analyze gene expression of lineage markers and cell cycle regulators

• Assess morphological maturation and enucleation capacity

How should conflicting results in TFDP2 functional studies be reconciled?

When facing conflicting results in TFDP2 research, consider these methodological approaches to reconciliation:

Common sources of discrepancy:

• Cell type-specific functions:

  • TFDP2 shows distinct roles in different cellular contexts:

    • Promotes erythroid differentiation

    • Facilitates viral replication in infected cells

    • Blocks adipocyte differentiation

  • Resolution: Specify cell type context in all comparisons and avoid generalizing findings

• Interaction partner differences:

  • TFDP2 partners with different E2F family members:

    • E2F2 in erythroid differentiation

    • Potentially other E2F factors in different contexts

  • Resolution: Characterize specific E2F partners in each experimental system

• Transcriptional activator vs. repressor functions:

  • TFDP2:E2F2 acts as a transcriptional repressor in terminally dividing erythroblasts

  • May function differently in other contexts

  • Resolution: Determine target gene expression changes in each specific context

Reconciliation approaches:

• Direct experimental comparison:

  • Repeat experiments using identical protocols across different model systems

  • Use the same antibodies, knockdown methods, and analytical approaches

  • Control for cell density, passage number, and culture conditions

• Mechanistic dissection:

  • Identify context-specific cofactors that might alter TFDP2 function

  • Examine post-translational modifications in different cell types

  • Analyze differential protein complex formation

• Domain-specific functions:

  • Map functional domains responsible for different activities

  • Create domain-specific mutants to separate functions

  • Identify cell-type specific splice variants

Data interpretation framework:
When evaluating conflicting literature, create a table mapping:

• Cell/tissue type

• Experimental approach

• TFDP2 binding partners

• Observed phenotypes

• Downstream targets affected

This structured approach will help identify patterns explaining apparent contradictions in TFDP2 functions.

How can researchers distinguish between direct and indirect effects of TFDP2 manipulation?

Distinguishing direct from indirect effects of TFDP2 manipulation requires systematic experimental approaches:

Methodological strategies:

• Temporal analysis:

  • Perform time-course experiments after TFDP2 manipulation

  • Early effects (6-12 hours) are more likely direct

  • Late effects (24-48 hours) often represent secondary consequences

  • Example: Monitor gene expression changes at multiple time points after knockdown

• Chromatin occupancy studies:

  • ChIP-seq to identify direct TFDP2 binding sites

  • Compare binding data with expression changes

  • Genes showing both binding and expression changes are likely direct targets

  • Focus on the E2 recognition site (5'-TTTC[CG]CGC-3')

• Transcriptional inhibition tests:

  • Use actinomycin D to block new transcription

  • Compare effects with and without transcriptional inhibition

  • Direct effects should be independent of new transcription

• Rapid protein depletion:

  • Use degron systems for acute TFDP2 depletion

  • Auxin-inducible or dTAG degron systems allow protein removal within minutes

  • Compare with slower shRNA approaches

Validation approaches:

• Reporter assays:

  • Test direct regulation of potential target promoters

  • Mutate TFDP2 binding sites to confirm specificity

  • Example: Luciferase reporter assays validated direct GATA1/TAL1 regulation of TFDP2

• Rescue experiments:

  • Restore only specific TFDP2 functions through domain mutants

  • Compare rescue efficiency for different phenotypes

  • Differential rescue suggests separate mechanisms

• Pathway inhibition:

  • Block specific downstream pathways

  • Determine which TFDP2-dependent phenotypes are affected

  • Helps map the hierarchy of effects

Example from literature:
In erythroid differentiation studies, researchers identified direct TFDP2 targets through:

• Global gene expression analysis

• Examination of E2F2 target genes

• Correlation with cell cycle phase abnormalities

• Validation through functional assays

What are the latest developments in understanding TFDP2's role in disease pathogenesis?

Recent research has expanded our understanding of TFDP2's implications in disease contexts:

Cancer associations:

• TFDP2 has been linked to multiple cancer types:

  • Retinoblastoma

  • Head and neck neoplasms

  • Female urogenital diseases and ovarian neoplasms

  • Thyroid diseases

  • Carcinoma, including squamous cell carcinoma

Mechanistic insights:

• Cell cycle dysregulation:

  • Aberrant TFDP2 expression may disrupt normal cell cycle control

  • TFDP2:E2F complex functions in G1 to S phase progression

  • Potential impact on cellular proliferation and tumor growth

• Differentiation block:

  • TFDP2 blocks adipocyte differentiation through CEBPA repression

  • Similar mechanisms might operate in other tissues

  • Could contribute to dedifferentiation in malignancies

• Viral pathogenesis:

  • TFDP2 upregulation facilitates PRRSV proliferation

  • C/EBPβ-dependent induction mechanism identified

  • Suggests potential role in other viral infections

Emerging research directions:

• Therapeutic targeting:

  • Disrupting TFDP2:E2F interactions as potential intervention

  • Cell type-specific TFDP2 modulation

  • Exploiting synthetic lethality in cancer contexts

• Biomarker development:

  • TFDP2 expression as prognostic indicator

  • TFDP2 pathway activation signatures

  • Antibody-based detection in clinical samples

• Developmental disorders:

  • Association with Alstrom Syndrome

  • Potential implications in embryonic development

  • Role in tissue-specific differentiation programs

Methodological advances:
Recent development of recombinant monoclonal antibodies against TFDP2 (e.g., 84408-2-PBS, 84408-4-PBS) provides new tools for consistent, reproducible analysis of TFDP2 in disease contexts.

How might single-cell approaches advance our understanding of TFDP2 function?

Single-cell technologies offer powerful new approaches to elucidate TFDP2 biology:

Methodological applications:

• Single-cell RNA sequencing (scRNA-seq):

  • Reveal cell-to-cell variability in TFDP2 expression

  • Identify subpopulations with distinct TFDP2 activity

  • Map TFDP2 expression to specific cell cycle phases

  • Track dynamic changes during differentiation trajectories

  • Particular relevance for heterogeneous systems like erythropoiesis

• Single-cell ATAC-seq:

  • Assess chromatin accessibility at TFDP2 binding sites

  • Correlate with gene expression patterns

  • Map regulatory landscape changes during differentiation

  • Identify cell state-specific enhancer usage

• Single-cell proteomics:

  • Protein-level validation of TFDP2 expression

  • Co-detection with interaction partners

  • Phosphorylation state analysis

  • Subcellular localization patterns

• Multimodal approaches:

  • CITE-seq: Combine surface marker and transcriptome analysis

  • SHARE-seq: Chromatin accessibility and gene expression

  • Spatial transcriptomics: Tissue context of TFDP2 expression

Research questions addressable with single-cell approaches:

• Cell cycle heterogeneity:

  • How does TFDP2 function vary across cell cycle phases?

  • Are there distinct subpopulations with different TFDP2 activity levels?

  • Does TFDP2 show oscillatory expression patterns?

• Differentiation dynamics:

  • Precise timing of TFDP2 upregulation during differentiation

  • Correlation with fate decision points

  • Identification of TFDP2-dependent branch points in development

• Disease heterogeneity:

  • TFDP2 expression variation in tumor cells

  • Correlation with therapy resistance subpopulations

  • Microenvironmental influences on TFDP2 function

Experimental design considerations:

• Include cell cycle phase markers in analysis

• Consider developmental timing in differentiation systems

• Use TFDP2 perturbation followed by single-cell analysis

• Integrate with bulk methods for validation and deeper mechanistic insights